FdaApplication
NDA 021368
Identifiers
- fda_app_no: NDA021368
Properties
| Property | Value |
|---|---|
| applicant_name | ELI LILLY AND CO |
| application_type | NDA |
| approval_date | 2003-11-21 |
Revenue by product
CIALIS
| Period | Revenue |
|---|---|
| Q3 2024 | $91.5M |
| Q2 2024 | $87.7M |
| Q1 2024 | $139.3M |
| Q4 2023 | $78.7M |
| Q3 2023 | $86.8M |
| Q2 2023 | $115.6M |
| Q1 2023 | $100.3M |
| Q4 2022 | $106.9M |
| Q3 2022 | $115.7M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| CIALIS | TADALAFIL | 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
| CIALIS | TADALAFIL | 10MG | TABLET;ORAL |
| CIALIS | TADALAFIL | 20MG | TABLET;ORAL |
| CIALIS | TADALAFIL | 5MG | TABLET;ORAL |
4 products